BOLINGBROOK, Ill., June 15, 2023 /PRNewswire/ -- ATI Physical Therapy, Inc. ("ATI" or the "Company") (NYSE: ATIP), a nationally recognized outpatient physical therapy provider in the United States, today announced that it has completed its previously disclosed Transaction Support Agreement (the "TSA") to increase the Company's liquidity and financial flexibility.
"We are pleased to complete this important step toward strengthening our balance sheet, a key component of ATI's continued transformation," said Sharon Vitti, Chief Executive Officer. "The TSA reflects months' of constructive engagement with our largest shareholders, underscores their confidence in the significant value creation opportunities ahead for ATI, and we believe fuels our return to growth."
As announced on March 6, 2023, the transactions completed in the TSA will enable ATI to obtain a $25 million delayed draw facility in the form of new second lien PIK exchangeable notes and exchange $100 million of first lien term loan into new second lien PIK exchangeable notes, among other things.
Ms. Vitti added, "Completing the TSA transactions provides us the flexibility we need to continue executing on our strategic initiatives – focused on our pipeline, provider base and provider productivity – as we deliver value to our patients, shareholders and other stakeholders. We are pleased with our solid performance through Q2 to date."
Andrew Shannahan, partner at Knighthead Capital Management, LLC, the investment advisor to ATI's largest shareholders, said, "Our continued support of ATI is further testament to our belief in ATI's growth potential and our confidence in Sharon and her new leadership team's ability to deliver on their strategic plan."
Execution of the TSA transactions were subject to shareholder vote and approval, which were completed Tuesday, June 13, 2023. Additional information is available on the Company's Current Report on Form 8-K filed today with the U.S. Securities and Exchange Commission (the "SEC") and in ATI's definitive proxy statement filed with the SEC on May 1, 2023 (as supplemented on June 5, 2023), which is available free of charge at the SEC's website, www.sec.gov, and on ATI's website at https://investors.atipt.com.
ABOUT ATI PHYSICAL THERAPY
At ATI Physical Therapy, we are passionate about potential. Every day, we restore it in our patients and activate it in our team members in our more than 900 locations in 24 states. With outcomes from more than 3 million unique patient cases, ATI is making strides in the industry by setting quality standards designed to deliver predictable outcomes for our patients with musculoskeletal (MSK) issues. ATI's offerings span across a broad spectrum for MSK-related issues. From preventative services in the workplace and athletic training support to outpatient clinical services and online physical therapy via our online platform, CONNECT™, a complete list of our service offerings can be found at ATIpt.com. ATI is based in Bolingbrook, Illinois.
Forward-Looking Statements
All statements other than statements of historical facts contained in this communication are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of the words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "project," "forecast," "predict," "potential," "seem," "seek," "future," "outlook," "target" or similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the impact of physical therapist attrition and ability to achieve and maintain clinical staffing levels and clinician productivity, anticipated visit and referral volumes and other factors on the Company's overall profitability, and estimates and forecasts of other financial and performance metrics and projections of market opportunity. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of the Company's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of the Company.
These forward-looking statements are subject to a number of risks and uncertainties, including:
If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements.
Investors should also review those factors discussed in the Company's amended S-1 registration statement filed with the SEC on April 12, 2022 under the heading "Risk Factors," our Form 10-K for the fiscal year ended December 31, 2022, the S-3 registration statement and amendments thereto dated August 10, 2022 and other documents filed, or to be filed, by ATI with the SEC. New risk factors emerge from time to time and it is not possible to predict all such risk factors, nor can the Company assess the impact of all such risk factors on the business of the Company or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. Readers should not place undue reliance on forward-looking statements. The Company undertakes no obligations to publicly update or revise any forward-looking statements after the date they are made or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or otherwise, except as required by law.
In addition, statements of belief and similar statements reflect the beliefs and opinions of the Company on the relevant subject. These statements are based upon information available to the Company, as applicable, as of the date of this communication, and while the Company believes such information forms a reasonable basis for such statements, such information may be limited or incomplete, and statements should not be read to indicate that the Company has conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements.
Category: Corporate Transactions
Contacts:
Investor Relations
Joanne Fong
SVP, Treasurer and Head of Investor Relations
ATI Physical Therapy
This email address is being protected from spambots. You need JavaScript enabled to view it.
630-296-2223 ext. 7131
Media
Genesa Garbarino
Garbo Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
424-499-7025
Rob Manker
Director of Customer Marketing & Public Relations
ATI Physical Therapy
This email address is being protected from spambots. You need JavaScript enabled to view it.
630-296-2222 ext. 7432
Last Trade: | US$2.71 |
Daily Change: | 0.92 51.40 |
Daily Volume: | 20,861 |
Market Cap: | US$11.440M |
November 04, 2024 August 05, 2024 May 01, 2024 February 26, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load